Drug Profile
Research programme: disease therapeutics - AstraZeneca/INSERM
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator INSERM; MedImmune
- Developer AstraZeneca; INSERM
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Respiration disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in France
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in France
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in France